Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate
Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…Abstract Number: 2772 • 2019 ACR/ARP Annual Meeting
Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Background/Purpose: RA patients often inquire about dietary interventions to improve disease control, as they perceive quick changes in pain and/or swelling after consumption of certain…Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable remission may be feasible in a subset of patients…Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting
Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…Abstract Number: 2775 • 2019 ACR/ARP Annual Meeting
Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort
Background/Purpose: Only scarce data is available on regarding pregnancy rates and pregnancy outcomes in early axial spondyloarthritis (axSpA). The objectives of this study were to…Abstract Number: 2776 • 2019 ACR/ARP Annual Meeting
5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Background/Purpose: Only scarce date is available on the long term treatment effect in a real-life setting (i.e. effectiveness) of TNFi in early axial SpA forms…Abstract Number: 2777 • 2019 ACR/ARP Annual Meeting
What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria,…Abstract Number: 2778 • 2019 ACR/ARP Annual Meeting
Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort…Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting
Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors
Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…Abstract Number: 2781 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk for cardiovascular disease (CVD). SLE itself predisposes patients to accelerated atherosclerosis. In addition, the…Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…Abstract Number: 2783 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has a primary role in the treatment of systemic lupus erythematous (SLE). Beyond its pleiotropic immunomodulatory effects on TLR…Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
- « Previous Page
- 1
- …
- 941
- 942
- 943
- 944
- 945
- …
- 2425
- Next Page »